We are live on ! Find out more
MLYS icon

Mineralys Therapeutics
MLYS

68 hedge funds and large institutions have $429M invested in Mineralys Therapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

244% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 9

11% more capital invested

Capital invested by funds: $385M → $429M (+$43.8M)

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

1% more funds holding

Funds holding: 67 → 68 (+1)

1.4% more ownership

Funds ownership: 60.24% → 61.64% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
68
Holders Change
+1
Holders Change %
+1.49%
% of All Funds
1.07%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
31
Reduced
9
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.9M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$9.48M
3
BlackRock
BlackRock
New York
+$2.01M
4
DM
Deerfield Management
New York
+$1.61M
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.52M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$7.43M
2
LGM
Logos Global Management
California
-$4.7M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.99M
4
SCM
Soleus Capital Management
Connecticut
-$2.94M
5
OM
Opaleye Management
Massachusetts
-$1.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ensign Peak Advisors
26
Ensign Peak Advisors
Utah
$2.13M – – –
SSA
27
Schonfeld Strategic Advisors
New York
$2M +$422K +28,266 +32%
Northern Trust
28
Northern Trust
Illinois
$1.92M +$180K +12,037 +12%
Charles Schwab
29
Charles Schwab
California
$1.63M +$101K +6,731 +8%
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
$1.51M +$1.52M +101,724 New
PCM
31
Pentwater Capital Management
Florida
$1.36M +$149K +10,000 +14%
SCM
32
Soleus Capital Management
Connecticut
$1.31M -$2.94M -196,424 -72%
AAA
33
Affinity Asset Advisors
New York
$1.07M – – –
Prudential Financial
34
Prudential Financial
New Jersey
$866K +$2.99K +200 +0.4%
Morgan Stanley
35
Morgan Stanley
New York
$855K +$301K +20,114 +67%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$686K +$104K +6,925 +21%
Point72 Asset Management
37
Point72 Asset Management
Connecticut
$665K +$508K +34,000 +680%
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$639K – – –
AA
39
ALPS Advisors
Colorado
$512K +$449K +30,031 New
PAM
40
Panagora Asset Management
Massachusetts
$392K +$344K +23,016 New
Federated Hermes
41
Federated Hermes
Pennsylvania
$351K +$308K +20,593 New
N
42
Nuveen
North Carolina
$327K +$45.2K +3,021 +19%
Goldman Sachs
43
Goldman Sachs
New York
$278K -$171K -11,439 -41%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$254K +$58.8K +3,935 +36%
Bank of America
45
Bank of America
North Carolina
$209K -$26.3K -1,761 -13%
PHP
46
Parkman Healthcare Partners
Connecticut
$199K +$24.8K +1,658 +17%
LBA
47
Letko, Brosseau & Associates
Quebec, Canada
$194K +$170K +11,400 New
AllianceBernstein
48
AllianceBernstein
Tennessee
$189K +$166K +11,080 New
JP Morgan Chase
49
JP Morgan Chase
New York
$184K +$23.2K +1,551 +17%
GCM
50
Ghisallo Capital Management
Massachusetts
$171K – – –
1
2
3 4

MLYS Hedge Fund Activity: Q2 2023 in Review

68 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q2 2023, worth a combined $429M — up 11% from $385M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new MLYS positions and 10 closed out — a net gain of 1 holder — while 31 added to existing stakes and 9 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $10.9M. The largest seller was Avidity Partners Management, cutting an estimated $7.43M.

  • 68 institutional investors held Mineralys Therapeutics (MLYS) as of Q2 2023, up from 67 in Q1 2023.
  • Funds reported $429M of Mineralys Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
  • 11 funds opened new Mineralys Therapeutics positions in Q2 2023 and 10 closed out, a net change of +1 holder.
  • The largest Mineralys Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $10.9M added.
  • The largest Mineralys Therapeutics seller in Q2 2023 was Avidity Partners Management, an estimated $7.43M sold.

Based on aggregated 13F filings for Q2 2023.